Factors in Selecting First-Line Therapy for Patients With Advanced RCC

Video

Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.

Recent Videos
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Related Content